Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Centessa Pharmaceuticals (CNTA) Liabilities and Shareholders Equity (2021 - 2026)

Centessa Pharmaceuticals has reported Liabilities and Shareholders Equity over the past 5 years, most recently at $687.5 million for Q4 2025.

  • Quarterly Liabilities and Shareholders Equity rose 19.19% to $687.5 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $2.2 billion through Dec 2025, up 12.66% year-over-year, with the annual reading at $687.5 million for FY2025, 19.19% up from the prior year.
  • Liabilities and Shareholders Equity was $687.5 million for Q4 2025 at Centessa Pharmaceuticals, up from $448.3 million in the prior quarter.
  • Over five years, Liabilities and Shareholders Equity peaked at $687.5 million in Q4 2025 and troughed at $328.2 million in Q1 2024.
  • The 5-year median for Liabilities and Shareholders Equity is $479.4 million (2022), against an average of $485.9 million.
  • Year-over-year, Liabilities and Shareholders Equity tumbled 30.63% in 2023 and then soared 61.57% in 2024.
  • A 5-year view of Liabilities and Shareholders Equity shows it stood at $629.6 million in 2021, then decreased by 29.43% to $444.3 million in 2022, then decreased by 18.92% to $360.2 million in 2023, then soared by 60.11% to $576.8 million in 2024, then grew by 19.19% to $687.5 million in 2025.
  • Per Business Quant, the three most recent readings for CNTA's Liabilities and Shareholders Equity are $687.5 million (Q4 2025), $448.3 million (Q3 2025), and $492.1 million (Q2 2025).